Government tightens oversight of GLP-1 drugs, flags risks amid rising demand; key details

by | Apr 1, 2026 | Asia

The Centre has issued a detailed advisory on GLP-1 receptor agonist drugs, emphasizing their use for type 2 diabetes and obesity must be strictly under medical supervision. Authorities are increasing regulatory surveillance and warning of strict action against violations in their sale or prescription.

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments